Singapore markets close in 3 hours 2 minutes

Corvus Pharmaceuticals, Inc. (CRVS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.1800+0.0400 (+1.87%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 136.36M
Enterprise value 115.27M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)4.09
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.36

Trading information

Stock price history

Beta (5Y monthly) 1.10
52-week change 3-9.92%
S&P500 52-week change 320.87%
52-week high 32.6900
52-week low 31.0500
50-day moving average 32.0326
200-day moving average 31.8153

Share statistics

Avg vol (3-month) 3222.55k
Avg vol (10-day) 3148.51k
Shares outstanding 562.55M
Implied shares outstanding 662.55M
Float 837.89M
% held by insiders 14.02%
% held by institutions 145.07%
Shares short (28 Jun 2024) 41.43M
Short ratio (28 Jun 2024) 47.96
Short % of float (28 Jun 2024) 42.84%
Short % of shares outstanding (28 Jun 2024) 42.29%
Shares short (prior month 31 May 2024) 41.52M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-29.33%
Return on equity (ttm)-60.46%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -22.95M
Net income avi to common (ttm)-24.86M
Diluted EPS (ttm)-0.5100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)22.13M
Total cash per share (mrq)0.35
Total debt (mrq)1.04M
Total debt/equity (mrq)3.12%
Current ratio (mrq)3.40
Book value per share (mrq)0.68

Cash flow statement

Operating cash flow (ttm)-20.98M
Levered free cash flow (ttm)-12.94M